Abstract

The germline mutation landscape in Chinese lung cancer patients has not been well defined. In this study, sequencing data of 1,021 cancer genes of 1,794 Chinese lung cancer patients was analyzed. A total of 111 pathogenic or likely pathogenic germline mutations were identified, significantly higher than non-cancer individuals (111/1794 vs. 84/10,588, p < 2.2e-16). BRCA1/2 germline mutations are associated with earlier onset age (median 52.5 vs 60 years-old, p = 0.008). Among 29 cancer disposition genes with germline mutations detected in Chinese cohort and/or TCGA lung cancer cohort, Only 11 from 29 genes are identified in both cohorts and BRCA2 mutations are significantly more common in Chinese cohort (p = 0.015). Chinese patients with germline mutations have different prevalence of somatic KRAS, MET exon 14 skipping and TP53 mutations compared to those without. Our findings suggest potential ethnic and etiologic differences between Western and Asian lung cancer patients.

Germline variants that predispose to lung cancer have been mostly studied in Western populations, but data from Chinese patients is lacking. Here the authors analyze lung cancer germline variants in 1794 Chinese patients, finding exclusive variants or with different frequency compared to TCGA data.

Details

Title
Clinical and genomic features of Chinese lung cancer patients with germline mutations
Author
Peng Wenying 1 ; Li, Bin 2 ; Li, Jin 3 ; Chang Lianpeng 3 ; Bai Jing 3 ; Yi Yuting 3 ; Chen, Rongrong 3 ; Zhang, Yanyan 3 ; Chen, Chen 3 ; Pu Xingxiang 4 ; Jiang Meilin 4 ; Li, Jia 4 ; Zhong Rui 4 ; Xu, Fang 4 ; Chen, Bolin 4 ; Xu, Li 4 ; Wang, Ning 5 ; Jiaojiao, Huan 3 ; Dai Pingping 3 ; Guan Yanfang 3 ; Yang, Ling 3 ; Xia Xuefeng 3 ; Yi, Xin 3 ; Wang, Jiayin 6 ; Yu Fenglei 7   VIAFID ORCID Logo  ; Wu, Lin 4   VIAFID ORCID Logo 

 Central South University, The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164); Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, The second department of Oncology, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960) 
 Central South University, Department of Oncology, Xiangya Hospital, Changsha, China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164); Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164) 
 Geneplus-Beijing, Beijing, China (GRID:grid.512993.5) 
 Central South University, The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164) 
 The PLA Rocket Force Characteristic Medical Center, Department of Oncology, Beijing, China (GRID:grid.488137.1) (ISNI:0000 0001 2267 2324) 
 Xi’an Jiaotong University, Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243) 
 The Second Xiangya Hospital of Central South University, Department of Thoracic Surgery, Changsha, China (GRID:grid.452708.c) (ISNI:0000 0004 1803 0208) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2637832735
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.